MGNX MACROGENICS INC
BULLISH
Impact: 7/10
8-K
8-K context-dependent: Items 8.01
Latest settled — T+20d ⚠ clustered
MGNX ▼ -12.50% at T+20d
LONG call ✗ call lost -12.50% · α vs SPY -20.07% · entry $3.44 → $3.01
Last close $4.53 (close May 22) · +31.69% from $3.44 entry
T+1d
+4.65%
call +4.65% · α +4.71%
$3.60
settled 6w ago
T+5d
-0.87%
call -0.87% · α -4.06%
$3.41
settled 6w ago
T+20d
-12.50%
call -12.50% · α -20.07%
$3.01
settled 18d ago
T+60d
—
call — · α —
—
in 6w
Price Chart
Loading chart...
Executive Summary
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, for gynecologic cancers. The company plans to resume enrollment and provide a mid-year program update.
Actionable Insight
The lifting of the clinical hold is a positive regulatory development for lorigerlimab, potentially accelerating enrollment and data readout. Monitor for mid-year update on clinical progress.
Key Facts
- FDA removed partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
- Study evaluates lorigerlimab in patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer
- To date, 41 patients have been dosed in the LINNET study
- Company plans to resume enrollment and provide mid-year 2026 update
Financial Impact
Positive for clinical development progress
clinical developmentdrug pipelineregulatory progress
Risk Factors
- Potential for future safety issues to re-emerge
- Clinical efficacy may not meet expectations in ongoing trial
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000026 |
| Exhibit: exhibit991_linnetstudyhold.htm | 0001125345-26-000026 |
| Document: 0001125345-26-000026-index-headers.html | 0001125345-26-000026 |
| Document: 0001125345-26-000026-index.html | 0001125345-26-000026 |
| Document: 0001125345-26-000026.txt | 0001125345-26-000026 |
7 reports for MGNX
75%
Hit rate
best @ T+20▲ +42.27%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
10d ago
|
8-K
| $4.16 $4.16 | · 0.00% | ▼ −0.01% | $4.53 (+8.89%) |
|
May 12, 2026
11d ago
|
8-K
| $3.52 $3.45 | ▼ −1.99% | ▼ −2.56% | $4.53 (+28.69%) |
|
May 11, 2026
12d ago
|
Press Release
| $3.52 $3.52 | · 0.00% | ▼ −0.54% | $4.53 (+28.69%) |
|
Apr 8, 2026
6w ago
|
8-K
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Apr 8, 2026
6w ago
|
Press Release
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Apr 8, 2026
6w ago
|
DEFA14A
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Feb 28, 2026
12w ago
|
Institutional Cluster
| $1.94 $1.90 | ▼ −2.06% | ▼ −1.15% | $4.53 (+133.51%) |
Showing 7 of 7
US Market Status
Market Closed — Opens Tue (35h 13m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access